Clinical Trials Browser

Interventional × Metastatic Castration-resistant Prostate Cancer × 90 days × Clear all

NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Phase 4 Active not recruiting

43 enrolled 16 charts

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06052306 2026-04-17

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 1 Active not recruiting

232 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06402331 2026-04-08

AlphaBreak

Phase 2 Active not recruiting

110 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06909825 2026-04-08

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 2 Active not recruiting

85 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT02044354 2026-04-01

CABA-DOC

Phase 3 Completed

195 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04853498 2026-03-31

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets

Phase 1 Terminated

192 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06193486 2026-03-31

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Phase 1 Recruiting

30 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06401980 2026-03-30

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 2 Recruiting

162 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07476001 2026-03-17

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

Phase 2 Recruiting

12 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

Phase 3 Active not recruiting

110 enrolled 12 charts

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04109729 2026-03-02

Rad2Nivo

Phase 1 Active not recruiting

39 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05125016 2026-02-27

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

Phase 1/2 Recruiting

370 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06533644 2026-02-27

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Recruiting

70 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04754191 2026-02-12

ENCORE

Phase 2 Active not recruiting

34 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07244341 2026-02-04

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 1 Recruiting

60 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT03732820 2026-01-29

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Phase 3 Active not recruiting

895 enrolled 19 charts 2 FDA

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06492122 2026-01-29

ProTACT

Phase 1 Recruiting

50 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07365995 2026-01-26

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Phase 3 Not yet recruiting

736 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer